Investigations have revealed upregulated expression of FTO (fat mass and obesity-associated gene), a known metabolic disease predictor, in both NAFLD patients and animal models and that abnormal hepatic signaling activity of FTO was associated with impaired metabolism in NAFLD [29]. The gene discussed is FTO; the disease is metabolic dysfunction-associated steatotic liver disease.